Needham & Company LLC Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

Posted by Francis Steltz on Aug 8th, 2026

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price target upped by equities research analysts at Needham & Company LLC from $236.00 to $240.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 16.99% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Guggenheim upped their price objective on Revolution Medicines from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Wedbush upped their price objective on shares of Revolution Medicines from $181.00 to $192.10 and gave the company an “outperform” rating in a report on Thursday, July 23rd. Royal Bank Of Canada increased their target price on shares of Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Piper Sandler lifted their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $153.05.

Check Out Our Latest Stock Analysis on RVMD

Revolution Medicines Trading Up 3.7%

Shares of Revolution Medicines stock opened at $205.15 on Thursday. Revolution Medicines has a 1 year low of $34.14 and a 1 year high of $205.90. The firm has a market cap of $43.97 billion, a PE ratio of -23.26 and a beta of 1.39. The stock has a fifty day moving average price of $176.66 and a 200-day moving average price of $137.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the prior year, the firm earned ($1.31) EPS. Equities research analysts anticipate that Revolution Medicines will post -7.92 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 10,020 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $1,564,322.40. Following the sale, the insider directly owned 267,330 shares in the company, valued at $41,735,559.60. This represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 29,600 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total transaction of $4,739,552.00. Following the completion of the sale, the chief operating officer directly owned 154,647 shares in the company, valued at approximately $24,762,077.64. The trade was a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 132,497 shares of company stock worth $21,470,486 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Meeder Advisory Services Inc. bought a new position in shares of Revolution Medicines in the second quarter worth $735,000. Citizens Financial Group Inc. RI bought a new position in Revolution Medicines in the 2nd quarter worth about $13,865,000. Deutsche Bank AG purchased a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $166,308,000. Alphabet Inc. purchased a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $551,843,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Revolution Medicines during the 2nd quarter valued at about $35,007,000. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

(Get Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.